In this summary report, we will take a quick look at the top 5 gainers and losers up or down double digits on the Canadian stock markets. Here is…
Search Results for: cybn
Cybin (CYBN.NEO), a Canadian-based biopharmaceutical company working to transform psychedelics into therapeutics, announced today that it had received approval from an independent ethics committee in the Netherlands to commence…
This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
Cybin (CYBN.NE) announced they are filing a new non-provisional patent application, their 14th patent application. The decision comes after what they called “a favourable international search report” relating to…
Doubling down on Cybin Back in January, Horizons’ (PYSK.NE) ETF held a relatively balanced portfolio of psychedelics companies. No company made up more than 10% of its holdings, with…
The NYSE Cybin (CYBN.N) just finished its first trading day on the New York Stock Exchange (NYSE) after announcing the upcoming uplisting last month. It was a less…
Cybin (CYBN.NE) announced today that it has closed its previously announced overnight marketed offering including the exercise in full of the over-allotment option granted to the Underwriters. “Investor demand…
Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on…
Back in January of this year, we told you about a psychedelics company that was going to come at that sector like many had talked about, but few had…